Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

N/ACompletedNCT00812188

University of Texas Southwestern Medical Center24 enrolled

Overview

Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Symmetric Limited Morphea

Interventions

Medium Dose UVA-1OTHER

UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.

High Dose UVA-1OTHER

High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female subjects 18 years of age or older. * Symmetric limited morphea. Exclusion Criteria: * Known sensitivity to fluocinonide 0.05% cream. * Clinical evidence of superinfected skin. * Immunocompromised state (including previously documented HIV). * Generalized Scleroderma. * Previous history of skin cancer. * Non-English speaking subjects.

Locations (1)

UT Southwestern Medical Center at Dallas - Department of Dermatology Clinical Trials

Dallas, Texas, United States

Outcomes

Primary Outcomes

Efficacy of UVA-1 treatment vs. topical steroid.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.